

ImmunoTools IT-Box-139 Award 2012



Yasmeen G. Ghnewa

PhD Supervisor: Dr. Derek Doherty

Trinity College Dublin (TCD), Phase I immunology,
Trinity centre for health sciences, St. James's hospital,
Dublin 8, Ireland

The role of natural killer T cells in the control of immune regulation, antigen presentation and antibody production by human B lymphocytes

I am approaching my second year of my PhD project (3 years to complete). The focus of my work and proposed title is "The effects of iNKT subsets on the B cell differentiation, activation and maturation in both health and disease (with chronic lymphocytic leukaemia being the disease of choice). So far I have been generating iNKT lines for the purpose of using them in co-culture experiments with B cells. I have done a couple of B cell experiments and have been looking at specific markers on B cells including CD19, CD27, CD5, CD38, CD24, CD1d, IgM, IgD, amongst others, with interesting results which I am currently teasing out.

As part of phenotyping my long term iNKT lines I will be using CD4, CD8 to look at the iNKT subtypes and CD31 along with others to look at cell age.

I currently and will continue to phenotype B cells and so far I have used CD27, and CD40, however I will soon be looking at activation markers including CD86, CD69.

In the near future I also plan to look at dendritic cell (DCs) interaction with iNKTs and therefore will need CD11c and CD14 as I will be using monocyte derived DCs.

ImmunoTools IT-Box-139 for Yasmeen G. Ghnewa include 100 antibodies

FITC - conjugated anti-human CD1a, CD3, CD4, CD5, CD6, CD7, CD8, CD14, CD15, CD16, CD19, CD21, CD25, CD29, CD35, CD36, CD41a, CD42b, CD45, CD45RA, CD45RB, CD45RO, CD49d, CD53, CD57, CD61, CD63, CD80, CD86, HLA-DR, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

PE - conjugated anti-human CD3, CD4, CD8, CD11b, CD15, CD14, CD18, CD19, CD20, CD21, CD22, CD31, CD33, CD38, CD40, CD45, CD45RB, CD50, CD52, CD56, CD58, CD62p, CD72, CD95, CD105, CD147, CD177, CD235a, HLA-ABC, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

PE/Dy647 -tandem conjugated anti-human CD3, CD4, CD8, CD14, CD19, CD20, CD25, CD54

APC -conjugated anti-human CD2, CD3, CD4, CD8, CD10, CD11a, CD11c, CD14, CD16, CD27, CD37, CD42b, CD44, CD45, CD59, CD62L, CD69, CD71, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

[DETAILS](#)

